These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 22681244)

  • 1. Daily dosing prophylaxis for haemophilia: a randomized crossover pilot study evaluating feasibility and efficacy.
    Lindvall K; Astermark J; Björkman S; Ljung R; Carlsson KS; Persson S; Berntorp E
    Haemophilia; 2012 Nov; 18(6):855-9. PubMed ID: 22681244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
    Roosendaal G; Lafeber FP
    Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose secondary prophylaxis reduces joint bleeding in severe and moderate haemophilic children: a pilot study in China.
    Wu R; Luke KH; Poon MC; Wu X; Zhang N; Zhao L; Su Y; Zhang J
    Haemophilia; 2011 Jan; 17(1):70-4. PubMed ID: 20579111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
    Dodd C; Watts RG
    Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in prophylactic therapy for persons with hemophilia.
    Dunn AL; Abshire TC
    Acta Haematol; 2006; 115(3-4):162-71. PubMed ID: 16549891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylactic factor replacement in hemophilia.
    Carcao MD; Aledort L
    Blood Rev; 2004 Jun; 18(2):101-13. PubMed ID: 15010149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis for severe haemophilia: clinical and economical issues.
    Fischer K; Van Den Berg M
    Haemophilia; 2003 Jul; 9(4):376-81. PubMed ID: 12828671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevention of joint damage in hemophilic children with early prophylaxis].
    Kreuz W; Escuriola Ettingshausen C; Funk M; Pons S; Schmidt H; Kornhuber B
    Orthopade; 1999 Apr; 28(4):341-6. PubMed ID: 10335528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The current status of prophylactic replacement therapy in children and adults with haemophilia.
    Ljung R; Gretenkort Andersson N
    Br J Haematol; 2015 Jun; 169(6):777-86. PubMed ID: 25819695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term low-dose secondary prophylaxis for severe/moderate haemophilia A children is beneficial to reduce bleed and improve daily activity, but there are obstacle in its execution: a multi-centre pilot study in China.
    Tang L; Wu R; Sun J; Zhang X; Feng X; Zhang X; Luke KH; Poon MC
    Haemophilia; 2013 Jan; 19(1):27-34. PubMed ID: 23231016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prophylaxis in patients with haemophilia complicated by inhibitors].
    Paweł Ł
    Pol Merkur Lekarski; 2011 Mar; 30(177):211-4. PubMed ID: 21545000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
    Crivianu-Gaita V; Rivard GE; Carcao M; Teitel J; St-Louis J; Blanchette V; Pullenayegum E; Abad A; Feldman BM
    Haemophilia; 2016 Sep; 22(5):e401-5. PubMed ID: 27481574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing factor prophylaxis for the haemophilia population: where do we stand?
    Blanchette VS; Manco-Johnson M; Santagostino E; Ljung R
    Haemophilia; 2004 Oct; 10 Suppl 4():97-104. PubMed ID: 15479380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orthopaedic evaluation in children with severe haemophilia A or B submitted to primary prophylaxis therapy in a coagulopathy treatment centre.
    De Podestá Haje D; Ono F; De Oliveira GB; Almeida J; De Paula JC; Batista Neto LV; Silva Barros SB
    Haemophilia; 2011 Mar; 17(2):228-32. PubMed ID: 21070500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current situation of regular replacement therapy (prophylaxis) for haemophilia in Japan.
    Taki M; Shirahata A
    Haemophilia; 2009 Jan; 15(1):78-82. PubMed ID: 18700841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.
    Risebrough N; Oh P; Blanchette V; Curtin J; Hitzler J; Feldman BM
    Haemophilia; 2008 Jul; 14(4):743-52. PubMed ID: 18422610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized prophylaxis.
    Collins PW
    Haemophilia; 2012 Jul; 18 Suppl 4():131-5. PubMed ID: 22726096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
    Biss TT; Chan AK; Blanchette VS; Iwenofu LN; McLimont M; Carcao MD; ;
    Haemophilia; 2008 Sep; 14(5):923-30. PubMed ID: 18637844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.